XSTOPAX
Market cap112mUSD
Dec 23, Last price
65.20SEK
1D
0.31%
1Q
12.41%
IPO
479.56%
Name
Paxman AB (publ)
Chart & Performance
P/E
148.81
P/S
5.90
EPS
0.44
Div Yield, %
0.00%
Shrs. gr., 5y
3.57%
Rev. gr., 5y
29.35%
Revenues
210m
+34.05%
Net income
8m
P
CFO
16m
+481.98%
Earnings
May 23, 2025
Profile
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 210,117 34.05% | 156,746 62.93% | 96,202 23.25% | ||||
Cost of revenue | 63,698 | 57,325 | 62,417 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 146,419 | 99,421 | 33,785 | ||||
NOPBT Margin | 69.68% | 63.43% | 35.12% | ||||
Operating Taxes | (361) | 1,762 | 106 | ||||
Tax Rate | 1.77% | 0.31% | |||||
NOPAT | 146,780 | 97,659 | 33,679 | ||||
Net income | 8,330 -180.69% | (10,324) -19.19% | (12,776) -33.41% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 128,354 | ||||||
BB yield | -11.30% | ||||||
| Debt | |||||||
Debt current | 11,038 | 12,728 | 11,328 | ||||
Long-term debt | 2,532 | 4,257 | 5,826 | ||||
Deferred revenue | 4,257 | 5,826 | |||||
Other long-term liabilities | 3,961 | (4,257) | (5,826) | ||||
Net debt | (11,411) | (21,155) | (55,159) | ||||
| Cash flow | |||||||
Cash from operating activities | 15,632 | 2,686 | (4,143) | ||||
CAPEX | (11,724) | (35,692) | (23,796) | ||||
Cash from investing activities | (25,329) | (36,691) | (24,446) | ||||
Cash from financing activities | (3,414) | (169) | 97,278 | ||||
FCF | 144,413 | 79,464 | 22,667 | ||||
| Balance | |||||||
Cash | 24,981 | 38,092 | 72,266 | ||||
Long term investments | 48 | 47 | |||||
Excess cash | 14,475 | 30,303 | 67,503 | ||||
Stockholders' equity | 27,342 | 8,688 | 6,236 | ||||
Invested Capital | 124,013 | 120,374 | 136,673 | ||||
ROIC | 120.12% | 75.99% | 33.85% | ||||
ROCE | 104.47% | 76.18% | 23.49% | ||||
| EV | |||||||
Common stock shares outstanding | 19,081 | 19,012 | 17,471 | ||||
Price | 36.80 -14.62% | 43.10 -33.69% | 65.00 155.91% | ||||
Market cap | 702,180 -14.31% | 819,439 -27.84% | 1,135,604 179.21% | ||||
EV | 690,769 | 808,608 | 1,093,221 | ||||
EBITDA | 165,029 | 116,839 | 47,254 | ||||
EV/EBITDA | 4.19 | 6.92 | 23.13 | ||||
Interest | 4,663 | 7,346 | 2,096 | ||||
Interest/NOPBT | 3.18% | 7.39% | 6.20% | ||||